Satisfaction and perceived effectiveness in patients on subcutaneous immunotherapy with a high-dose hypoallergenic pollen extract.

Autor:	Rodríguez Mosquera M; Hospital Universitario Puerta de Hierro Majadahonda, Servicio de Alergia, Majadahonda, Spain. Phone: +34 91 191 68 04 Fax: +34 91 373 46 61 E-mail: mrodriguezm.hpth@salud.madrid.org., Sola Martínez FJ; Hospital Universitario Ramón y Cajal, Servicio de Alergia, Madrid, Spain., Montoro de Francisco A; Hospital central de la defensa Gómez Ulla, Instituto Mixto de Investigación del Defensa IMIDEF, Servicio de Alergia, Madrid, Spain., Chivato Pérez T; Facultad de Medicina, Universidad CEU San Pablo, Madrid, Spain., Sánchez Moreno V; Hospital Universitario del Henares Madrid, Servicio de Alergología, Madrid, Spain., Rodríguez-Marco A; Departamento Médico, Merck SL, Madrid, Spain., Hernández-Peña J; Departamento Médico, Merck SL, Madrid, Spain.
Jazyk:	angličtina
Zdroj:	European annals of allergy and clinical immunology [Eur Ann Allergy Clin Immunol] 2016 Sep; Vol. 48 (5), pp. 188-93.
Abstrakt:	This study was designed to determine the level of satisfaction, tolerance and perceived effectiveness by patients in the first pollen season after starting treatment with Alergovit(®). For this purpose, a nationwide, retrospective, multicentre and cross-sectional observational study was carried on 256 patients. Perceived effectiveness by the patients was measured using a visual analogue scale and was clinically significant in 92.4% of the patients. The satisfaction level was evaluated with a specific questionnaire. 32.5% of the patients were totally satisfied with Allergovit(®) and 48.8% reported a high degree of satisfaction. The treatment was well tolerated by 99.2% of the patients. Our results demonstrate that subcutaneous immunotherapy with Allergovit(®) is effective and well-tolerated in routine clinical practice.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu